Which Treatment Matches Your BMI And Weight Goals?
BMI For Wegovy vs Mounjaro: Understanding Your Options
The BMI requirements for Wegovy and Mounjaro are identical under UK licensing, making your choice dependent on other factors rather than eligibility alone. Both treatments are licensed for weight management in adults with a BMI of 30 kg/m² or above, or those with a BMI of 27 kg/m² or above who have at least one weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnoea. The key difference lies in their mechanisms of action: Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors for dual hormonal action.
When considering BMI for Wegovy versus Mounjaro, it's important to understand that both require the same commitment to lifestyle changes alongside medication. Your prescriber will assess not just your BMI, but your medical history, current medications, and weight loss goals to determine which option may be more suitable. Both treatments must be used alongside a reduced-calorie diet and increased physical activity, and both require gradual dose escalation to minimise potential side effects whilst maximising effectiveness.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison
Understanding the cost implications when choosing between treatments based on BMI for Wegovy or Mounjaro helps you plan your weight management journey effectively. Wegovy pricing starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance dose of 2.4mg at £209.99. Mounjaro follows a different dosing schedule with six available strengths from 2.5mg to 15mg, with pricing varying accordingly. New customers can apply discount code FIRST40 at checkout, while returning customers use code DOSE25 to access these competitive prices.
Our bundle options provide convenient supply continuity for both treatments, particularly valuable when establishing your optimal BMI response to either Wegovy or Mounjaro. The Intro Trio bundle (0.25mg, 0.5mg & 1mg Wegovy) costs £299.99, covering your first three months of dose escalation, while the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. Both medications require prescription-only access through our clinical assessment process, ensuring you receive appropriate monitoring and support throughout your treatment.
Clinical Evidence For BMI Outcomes: STEP Trial Results
The clinical evidence supporting BMI improvements with Wegovy comes primarily from the landmark STEP trial programme. In the STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. The STEP 5 trial demonstrated that these BMI improvements were sustainable, with participants maintaining approximately clinically studied weight loss at two years.
When evaluating BMI outcomes for Wegovy vs Mounjaro, it's important to note that direct head-to-head trials are limited, and the studies used different methodologies. The SELECT cardiovascular outcomes trial showed that Wegovy reduced major cardiovascular events by 20% (HR 0.80), which is particularly relevant for individuals whose BMI qualifies them due to weight-related health conditions. NICE TA875 recommends Wegovy with specialist weight management support, recognising its evidence base for sustained BMI reduction.
How Wegovy Works For BMI Reduction
Understanding how Wegovy works helps explain its effectiveness for BMI reduction across different patient populations. Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist that mimics a natural hormone involved in blood sugar control and appetite regulation. When considering BMI for Wegovy treatment, the medication works by slowing gastric emptying, which helps you feel full sooner and stay satisfied longer after meals. It also acts on appetite centres in the brain, potentially reducing food cravings and the desire to eat between meals. This dual mechanism of promoting satiety and reducing appetite naturally leads to decreased caloric intake, which when combined with increased physical activity and dietary changes, supports sustainable BMI reduction over time.
Simple Ordering Process For Both Treatments
Accessing either Wegovy or Mounjaro based on your BMI requirements begins with our streamlined three-minute online clinical assessment. This comprehensive questionnaire captures your medical history, current BMI, previous weight loss attempts, and any existing health conditions that might influence treatment choice. Our qualified prescribers, operating under GPhC registration #9012878, review your assessment within three working days (or 24 hours with our express service) to determine your suitability for either treatment. Once approved, your prescription-only medicine is dispatched via next-day delivery using our temperature-controlled cold-chain system to ensure medication integrity. Our clinical team remains available throughout your treatment to address any questions about BMI progress, side effects, or dose adjustments.
Storage Requirements: Wegovy vs Mounjaro Practicalities
The storage requirements for BMI treatments differ between Wegovy and Mounjaro, which may influence your choice depending on your lifestyle and travel needs. Wegovy FlexTouch pens must be stored in the refrigerator at 2-8°C before first use, but offer superior room temperature stability, remaining effective for up to six weeks below 30°C once removed from refrigeration. Mounjaro, by contrast, can only be stored at room temperature for up to 21 days, making Wegovy more convenient for extended travel or situations where refrigeration access is limited. Both are administered once weekly via pre-filled injection pens, with dose escalation schedules designed to optimise BMI outcomes while minimising side effects. The injection technique is identical for both treatments, using the same simple subcutaneous injection into the abdomen, thigh, or upper arm.
BMI Monitoring And Treatment Progression
Successful BMI management with either Wegovy or Mounjaro requires careful monitoring and realistic expectations about treatment progression. Most patients begin seeing BMI changes within 4-12 weeks of starting treatment, though individual responses vary significantly based on starting BMI, adherence to dietary changes, exercise levels, and metabolic factors. Your prescriber will typically assess progress every 12-16 weeks, evaluating not just BMI reduction but overall health improvements, tolerance to treatment, and any necessary dose adjustments.
The relationship between starting BMI and treatment choice isn't straightforward – both Wegovy and Mounjaro have shown effectiveness across different BMI ranges within their licensed indications. Higher starting BMIs may require longer treatment durations to achieve target weight loss, while patients closer to the BMI threshold may reach their goals more quickly. Regular monitoring ensures that whichever treatment you choose continues to provide meaningful BMI benefits while maintaining an acceptable side effect profile.
Make Your Choice: Wegovy Or Mounjaro For Your BMI Goals
Choosing between Wegovy and Mounjaro for your BMI objectives ultimately depends on individual factors beyond the basic eligibility criteria. Both treatments are available through EverydayMeds with the same rigorous clinical oversight and next-day delivery service, ensuring you receive expert guidance regardless of which option you select. Our clinical team can help you weigh the practical considerations – from storage requirements and dosing schedules to cost implications and potential side effect profiles – to determine which treatment aligns best with your lifestyle and BMI targets. Start your clinical assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients, and take the first step towards achieving your weight management goals with professional support from our GPhC-registered pharmacy team at https://everydaymeds.co.uk/collections/weight-loss.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
